Bringing New Horizons to Therapy


General News

Ablatherm now reimbursed in France under a special innovative therapies regimen

The French National Authority for Health (HAS - Haute Autorité de Santé) granted Ablatherm® HIFU treatment temporary reimbursement authorization under a special regimen for innovative therapies. More than 10 years after obtaining CE marking, the temporary reimbursement is a major step towards acceptation of HIFU as a standard treatment for prostate cancer.
Print This Page